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Dabrafenib for cutaneous melanoma
infiltrating the vitreous: regression of
metastasis and occurrence of uveitis as a
secondary effect
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Abstract
Intraocular metastasis of cutaneous melanoma is extremely infrequent. This typically occurs in advanced metastatic
disease and has a poor survival prognosis. The most frequent reported treatment is radiotherapy. BRAF inhibitors
are new, orally administered and very effective drugs used for metastatic cutaneous melanoma. Herein, we report a
case of a 58-year-old patient with a recent diagnosis of cutaneous melanoma who consulted for floaters and
presented vitreous opacities in both eyes. A diagnostic vitrectomy of his left eye was performed and pathologic
analysis disclosed infiltrating melanoma cells in the vitreous. Treatment with dabrafenib (a type of BRAF inhibitor)
achieved the regression of the intraocular metastasis in the right eye. Moreover, the patient presented a severe
anterior uveitis due to dabrafenib, a well-known secondary effect of this drug.
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Introduction
Inhibitors of serine/threonine protein kinase B-Raf (so-
called BRAF inhibitors) have become a hopeful thera-
peutic option in patients with metastatic cutaneous
melanoma. There are two BRAF inhibitors: dabrafenib
and vemurafenib. Both are orally administered and both
have shown to provide a great benefit in terms of
increased survival in these patients [1]. Uveitis is a well-
known secondary effect of these types of drugs [2]. We
describe a patient who presented vitreous infiltration of
a cutaneous melanoma, who was effectively treated with
dabrafenib. Moreover, the patient presented a severe
anterior uveitis secondary to this drug.
Case report
A 58-year-old man consulted for blurry vision in both
eyes of 4 weeks duration. His past medical history was
relevant for cutaneous melanoma diagnosed 5 months
before. It was located in the lumbar region of his back.
Breslow’s depth was 1.8 mm and the sentinel node had
metastasis. He received surgery for this tumour and, at
the moment of consultation, he was under treatment
with adjuvant interferon alpha (20 million IU adminis-
tered subcutaneously three times a week). Visual acuity
was 20/32 in his right eye and 20/50 in his left eye;
anterior segment biomicroscopy revealed few cells and
intraocular pressure was 14 mmHg in both eyes.
Funduscopy revealed dense whitish vitreous opacities
without signs of chorioretinal inflammation. Optical
coherence tomography showed hyperreflective bands
anterior to the retina corresponding to the vitreous
opacities (Fig. 1). A diagnostic vitrectomy was performed
in the left eye and the cytological study revealed dis-
sociated cells forming irregular groups with atypia,
positive for homatropine methylbromide 45 (HMB45)
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by inmunohistochemistry, consistent with a metastatic
origin from a cutaneous melanoma (Figs. 2 and 3).
With the diagnosis of metastatic cutaneous melanoma,
and since the melanoma was positive for the V600 muta-
tion, interferon was replaced by dabrafenib. Brain and or-
bital magnetic resonance imaging were performed to rule
out extraocular involvement, with negative results. After
10 weeks of treatment with dabrafenib the patient con-
sulted for blurry vision and redness in his RE. Examination
revealed severe anterior uveitis and hypopyon. Topical
prednisolone with tapering doses and cycloplegic drops
were started, which successfully resolved the uveitis. This
was attributed to dabrafenib. A new ophthalmological
evaluation was performed after 16 weeks of dabrafenib
Fig. 1 Imaging on admission. a and b Retinographies showing dense vitreous opacities; a: right eye, b: left eye. c and d: optical coherence
tomography showing hyperreflective bands anterior to the retina (blue arrows); c right eye, d: left eye
Fig. 2 Pathologic analysis showing dissociated cells forming irregular groups with atypia (a–c), positive for HMB45 by inmunohistochemistry (d)
consistent with a metastatic origin from a cutaneous melanoma
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treatment, revealing a complete absence of vitreous opaci-
ties in the left eye (the vitrectomised eye) as well as in the
right eye, with visual acuity 20/20 in both eyes (Fig. 4).
Another examination performed after 24 weeks of dabra-
fenib treatment again showed complete absence of cellular
infiltration of the vitreous cavity in both eyes. Unfortu-
nately, the patient was diagnosed with liver metastasis in
the 32nd week of treatment and died shortly after.
Discussion
Metastasis of cutaneous melanoma to the eye is rare and
has a very poor survival prognosis. The uvea has been
found to harbour the majority of intraocular cutaneous
melanoma, with choroidal involvement occurring in
more than half of the cases [3]. Isolated vitreous metas-
tases are exceedingly rare with only a few cases reported
in the literature [4]. Different treatments have been re-
ported for its management, with radiotherapy the most
frequent. Other options include enucleation or eviscer-
ation, vitrectomy, subconjunctival chemotherapy, laser
photocoagulation and cryotherapy [3]. We used one of
the drugs approved for the treatment of metastatic cuta-
neous melanoma, dabrafenib. To our knowledge there
are no published reports on the use of dabrafenib for
cutaneous melanoma with intraocular metastasis. We
postulate that dabrafenib penetrates the blood-retinal
barrier well since it achieved a complete resolution of
vitreous infiltration in our case. Interestingly, a good
penetration of the blood-brain barrier by this drug has
been suggested due to its high clinical activity for central
nervous system metastasis of cutaneous melanoma in a
clinical trial [5]. Uveitis is a well-known secondary effect
of BRAF inhibitors. We recently described a series of pa-
tients with uveitis secondary to vemurafenib that re-
solved with local steroids and temporary withdrawal of
vemurafenib [6]. Our case developed a severe anterior
uveitis which also responded to topical steroids. Typic-
ally uveitis secondary to BRAF inhibitors is bilateral and
our case was unilateral. One potential mechanism for
the origin of the uveitis after BRAF inhibitor use is a dir-
ect action on intraocular metastatic cells [2]. This may
explain why our patient presented with unilateral uveitis
involving only the infiltrated non-vitrectomised eye.
In conclusion, the known efficacy of dabrafenib for
treating metastatic disease of cutaneous melanoma repli-
cated when the metastasis involved the vitreous. This
might be a safe and effective alternative for managing
this infrequent type of metastasis.
Fig. 4 Retinographies performed after 16 weeks of dabrafenib treatment showing complete resolution of vitreous opacities in the right eye
Fig. 3 Retinographies after diagnostic vitrectomy performed in the left eye
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